Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16064651 | 0.90 | SRD5A1 (0.51) | AKR1B1S1PR1CHEK1SRD5A1SRD5A2 | |
| SCHEMBL29008215 | 0.86 | CHEK1 (0.44) | CHEK1SRD5A2PDK2TSHR | |
| SCHEMBL4805957 | 0.86 | CASP1 (0.53) | AKR1B1 | |
| SCHEMBL9320759 | 0.83 | GRIN2B (0.47) | S1PR1CHRNB4CHRNA3CHRNA7GRIN2B | |
| SCHEMBL3051643 | 0.80 | TSHR (0.42) | CHEK1SRD5A2PDK2TSHR | |
| SCHEMBL17486940 | 0.78 | MAOA (0.61) | — | |
| SCHEMBL2965416 | 0.77 | TSHR (0.55) | SRD5A2PDK2TSHR | |
| SCHEMBL11620189 | 0.76 | AKR1B1 (0.39) | AKR1B1SRD5A1SRD5A2PARP11TSHR | |
| SCHEMBL2633408 | 0.76 | GRIN2B (0.46) | CHRNB4CHRNA3CHRNA7GRIN2BTSHR | |
| SCHEMBL6660057 | 0.76 | AKR1B1 (0.39) | AKR1B1SRD5A1SRD5A2PARP11TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092637-A1 | Novel compounds | XYLOGEN AB (SE) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092637-A1 | Novel compounds | ENTPD5, G6PD, G6PC1 | AKR1B1 441/4885S1PR1 1311/4885CHEK1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.